Paliperidone Palmitate Treatment Decisions for Schizophrenia
This paper examines three sequential psychopharmacological treatment decisions made for a client diagnosed with paranoid schizophrenia based on PANSS assessment results. The first decision selects Invega Sustenna (paliperidone palmitate) as a long-acting injectable antipsychotic over olanzapine and aripiprazole, citing superior tolerability and compliance advantages. The second decision addresses injection-site pain by switching from the gluteal to the deltoid site. The third decision confronts antipsychotic-induced weight gain, recommending diet, exercise counseling, and potential adjunctive metformin rather than switching medications, given the client's significant PANSS score improvements over two months of treatment.
- Introduction and Diagnosis: Paranoid schizophrenia diagnosis and treatment goals
- Decision 1: Selecting Invega Sustenna as the Initial Antipsychotic: Rationale for choosing paliperidone palmitate injectable
- Decision 2: Changing the Injection Site: Switching injection site to reduce patient pain
- Decision 3: Managing Antipsychotic-Induced Weight Gain: Lifestyle and metformin approach to weight management
- References: APA citations for pharmacological studies used
✍️ How to write this paper — guide, tools & examples ▾
What makes this paper effective
- Each clinical decision is structured with a clear rationale drawn directly from peer-reviewed literature, demonstrating evidence-based practice rather than unsupported clinical judgment.
- The paper integrates patient-reported outcomes (PANSS scores, subjective complaints) alongside pharmacological evidence, showing the balance between clinical data and individualized care.
- Decision 3 effectively uses a meta-analysis to argue against switching medications, demonstrating that the student can evaluate comparative evidence and resist reflexive prescribing changes.
Key academic technique demonstrated
The paper demonstrates sequential clinical reasoning: each decision builds on the outcome of the previous one, creating a coherent treatment narrative. This "decision-outcome-next decision" structure shows the student understands that psychopharmacological management is iterative, not static.
Structure breakdown
The paper opens with a brief diagnostic framing, then presents three numbered clinical decisions in chronological order. Each decision section states the choice made, provides the evidence-based rationale, and reports follow-up outcomes. The conclusion of Decision 3 anticipates contingencies (symptom worsening), showing forward clinical planning. A formal APA reference list closes the paper.
Introduction and Diagnosis
Based on her PANSS (Positive and Negative Syndrome Scale) test results, the client in this case has been diagnosed with schizophrenia, paranoid type, in which positive symptoms such as delusions are prevalent. The purpose of this paper is to clarify three key psychopharmacological treatment decisions made on behalf of the client. The goals of all three decisions are symptom reduction and the promotion of the client's mental health and psychosocial functioning.
Create your account
Always verify citation format against your institution’s current style guide requirements.